Ashkon Software



NVGN Stock - Novogen Limited

NVGN Intraday Chart

NVGN Profile

Novogen Limited logo

Novogen Limited, trading under the ticker symbol NVGN, was a biotechnology company that focused on the development of drugs for the treatment of cancer and other diseases. The company was headquartered in Sydney, Australia, and had a subsidiary in the United States.

Novogen's lead drug candidate was Cantrixil, a drug that was being developed for the treatment of ovarian cancer. The company also had other drug candidates in its pipeline that were being developed for the treatment of various cancers.

In 2017, Novogen merged with its subsidiary, to form Kazia Therapeutics Limited, and the company was delisted from the NASDAQ stock exchange.

Prior to its merger, as of its most recent financial filings, Novogen had a market capitalization of approximately $12 million and employed over 40 professionals across its various operations worldwide. The company faced challenges in securing funding for its research and development activities and in successfully developing and commercializing its drug candidates.

Investors who held NVGN stock should have received compensation from the merger. Investors who are interested in the biotechnology industry may want to research other publicly traded companies in the sector, evaluate their financial performance, competitive position, and growth prospects. The biotechnology industry is highly competitive, and the success of a company's research and development activities is


Copyright © 2000-2024, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer